Atypical hemolytic uremic syndrome due to DGKE mutation and response to eculizumab: lessons for the clinical nephrologist

J Nephrol. 2021 Aug;34(4):1331-1335. doi: 10.1007/s40620-020-00925-8. Epub 2021 Mar 22.
No abstract available

Keywords: Atypical hemolytic uremic syndrome (aHUS); Complement; Complement inhibitors; Genetics; Pediatrics.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Atypical Hemolytic Uremic Syndrome* / diagnosis
  • Atypical Hemolytic Uremic Syndrome* / drug therapy
  • Atypical Hemolytic Uremic Syndrome* / genetics
  • Diacylglycerol Kinase / genetics*
  • Humans
  • Infant
  • Male
  • Mutation
  • Nephrologists

Substances

  • Antibodies, Monoclonal, Humanized
  • eculizumab
  • DGKE protein, human
  • Diacylglycerol Kinase